Paul Brannelly's most recent trade in Collegium Pharmaceutical Inc was a trade of 5,927 Common Stock done at an average price of $26.0 . Disclosure was reported to the exchange on Feb. 10, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | Paul Brannelly | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.95 per share. | 10 Feb 2021 | 5,927 | 215,428 (0%) | 0% | 26.0 | 153,806 | Common Stock |
| Collegium Pharmaceutical Inc | Paul Brannelly | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.95 per share. | 10 Feb 2021 | 2,564 | 221,355 (0%) | 0% | 26.0 | 66,536 | Common Stock |
| Collegium Pharmaceutical Inc | Paul Brannelly | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 42,000 | 215,758 (0%) | 0% | 0 | Common Stock | |
| Collegium Pharmaceutical Inc | Paul Brannelly | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 8,161 | 223,919 (0%) | 0% | - | Common Stock |